Actilyse 50mg Injection
PDF Leaflet Revision Date: 19 November 2024
Clinical Summary
Quick overview from the medicine insert
Indication
Fibrinolytic therapy for acute myocardial infarction and massive pulmonary embolism.
Dosage (summary)
15 mg IV bolus, followed by 50 mg IV infusion over 30 mins, then 35 mg over 60 mins (max 100 mg). Adjust for weight < 65 kg.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Limited safety data; use only if benefits outweigh risks. Caution in breastfeeding.
Key Drug Interactions
- Anticoagulants
- ACE inhibitors
Contraindications
- Hypersensitivity to alteplase
- Active bleeding disorders
- Recent major surgery
- Uncontrolled hypertension
- Intracranial hemorrhage
Common side effects
- Bleeding
- Intracranial hemorrhage
- Dysrhythmias
Counselling Points
- Report any signs of bleeding immediately.
- Avoid other anticoagulants for 24 hours post-treatment.
- Ensure resuscitation equipment is available during administration.
Serious warnings
- Risk of serious bleeding
- Use only by experienced doctors
- Monitor blood pressure closely
Important Disclaimer
The Actilyse 50mg Injection professional information leaflet below is the property of Ingelheim Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
